SOPHARMA AD: Sales revenues for January 2025

opublikowano: 2025-02-20 13:07

Spis treści:

1. REPORT

2. INFORMATION ABOUT THE ENTITY

3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY


Spis załączników:
SFA_Sales_Revenues_January_2025_EN_espi.pdf  (REPORT)

POLISH FINANCIAL SUPERVISION AUTHORITY
UNI - EN REPORT No 9 / 2025
Date of issue: 2025-02-20
Short name of the issuer
SOPHARMA AD
Subject
Sales revenues for January 2025
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
Sofia, Bulgaria, February 20, 2025 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for January 2025 the Company recorded an increase in sales of 7% compared to the same month of the previous year, incl. 6% increase in domestic sales and 8% increase in export sales.
Annexes
File Description
SFA_Sales_Revenues_January_2025_EN_espi.pdfSFA_Sales_Revenues_January_2025_EN_espi.pdf Sales revenues for January 2025

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2025-02-20 Ognian Donev Executive director